Inicio › Linfoma de Burkitt › Florida

Ensayos clínicos de Linfoma de Burkitt en Florida

16 estudios sobre Linfoma de Burkitt buscan participantes en Florida.

Ciudades en Florida

Texto oficial del estudio (inglés)

Asciminib and Inotuzumab Ozogamicin for Relapsed or Refractory Philadelphia Chromosome-positive B-cell Acute Lymphoblastic Leukemia (R/R Ph+ B-ALL)

University of Miami Sylvester Comprehensive Cancer Center, Miami

ReclutandoFase 1

Edades de 18 en adelante · Todos los sexos · Actualizado el 13 nov 2026 · NCT07936266

Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia

Jupiter Medical Center, Jupiter

ReclutandoFase 2

Edades de 18 en adelante · Todos los sexos · Actualizado el 12 nov 2026 · NCT03739814

A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Golisano Children's Hospital of Southwest Florida, Fort Myers
UF Health Cancer Institute - Gainesville, Gainesville
Memorial Regional Hospital/Joe DiMaggio Children's Hospital, Hollywood
y 9 más

ReclutandoFase 2

Edades de 1 a 30 · Todos los sexos · Actualizado el 12 nov 2026 · NCT04546399

Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia

Memorial Regional Hospital/Joe DiMaggio Children's Hospital, Hollywood
Orlando Health Cancer Institute, Orlando

ReclutandoFase 3

Edades de 18 a 39 · Todos los sexos · Actualizado el 3 nov 2026 · NCT03150693

Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)

Johns Hopkins All Children's Hospital ( Site 1025), St. Petersburg

ReclutandoFase 1/2

6 Months – 25 Years · Todos los sexos · Actualizado el 30 oct 2026 · NCT06395103

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

UF Health Cancer Institute - Gainesville, Gainesville
Memorial Regional Hospital/Joe DiMaggio Children's Hospital, Hollywood
Nemours Children's Clinic-Jacksonville, Jacksonville
y 8 más

ReclutandoFase 2

365 Days · Todos los sexos · Actualizado el 27 oct 2026 · NCT06317662

A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

Golisano Children's Hospital of Southwest Florida, Fort Myers
UF Health Cancer Institute - Gainesville, Gainesville
Memorial Regional Hospital/Joe DiMaggio Children's Hospital, Hollywood
y 9 más

ReclutandoFase 2

366 Days – 46 Years · Todos los sexos · Actualizado el 27 oct 2026 · NCT06124157

Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)

Mayo Clinic, Clinical Trials Referral Office, Jacksonville

ReclutandoFase 1/2

Edades de 13 a 90 · Todos los sexos · Actualizado el 26 oct 2026 · NCT06533579

Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies

SSAK Partners, Coral Springs
Mayo Clinic - Jacksonville, Jacksonville

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 14 oct 2026 · NCT07648264

AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia

Research Site, Tampa

ReclutandoFase 1/2

Edades de 12 en adelante · Todos los sexos · Actualizado el 13 oct 2026 · NCT06137118

Blinatumomab Consolidation in Real World

Mayo Clinic Cancer Center, Jacksonville

ReclutandoEstudio observacionalSe aceptan voluntarios sanos

Edades de 18 en adelante · Todos los sexos · Actualizado el 1 oct 2026 · NCT07117136

Study of KTE-X19 in Minimal Residual Disease (MRD) Positive B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Moffitt Cancer Center, Tampa

ReclutandoFase 2

Edades de 18 en adelante · Todos los sexos · Actualizado el 25 sept 2026 · NCT06144606

Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)

H. Lee Moffitt Cancer Center, Tampa

ReclutandoFase 1

Edades de 18 en adelante · Todos los sexos · Actualizado el 8 sept 2026 · NCT03666000

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

Broward Health Medical Center, Fort Lauderdale
Golisano Children's Hospital of Southwest Florida, Fort Myers
UF Health Cancer Institute - Gainesville, Gainesville
y 12 más

ReclutandoFase 3

365 Days – 25 Years · Todos los sexos · Actualizado el 25 ago 2026 · NCT03959085

Study of SGR-1505 in Mature B-Cell Neoplasms

Napa Research, Pompano Beach

ReclutandoFase 1

Edades de 18 en adelante · Todos los sexos · Actualizado el 13 feb 2026 · NCT05544019

The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and Young Adults With B-ALL

University of Florida, Gainesville
Nicklaus Children's Hospital, Miami
Johns Hopkins All Children's Hospital, St. Petersburg

ReclutandoFase 2

Edades de 1 a 25 · Todos los sexos · Actualizado el 4 may 2025 · NCT03509961

De ClinicalTrials.gov, datos obtenidos el 15 nov 2026. Cada estudio establece sus propios criterios de elegibilidad; el equipo del estudio decide quién puede participar.